Blood & Marrow Stem Cell Transplant & Immune Cell Therapy

We are your trusted partner for bone marrow and stem cell transplants

Refer a Patient: 317.948.9012
BMT Banner 2024

When it comes to diagnosing and treating patients with complex cancers, like leukemia, lymphoma, multiple myeloma, or metastatic germ cell tumors like testicular cancer, you have access to the multidisciplinary team at Indiana University Health Medical Center, a partner to the only NCI-designated comprehensive cancer center in Indiana.

At IU Health Medical Center, your patients can access leading-edge cellular therapy. Our care team is shaping the future of cancer treatment with more than 30 years of clinical breakthroughs in these types of cancer. IU Health Medical Center continues to be nationally recognized by U.S. News & World Report Best Hospitals rankings, and our cancer program is rated high performing in 2025.

Our research and clinical teams in the IU Health Blood and Bone Marrow Stem Cell Transplant & Immune Cell Therapy Program have:

  • Developed the groundbreaking use of cord blood to treat cancer and immune disorders, now a reliable procedure that has been used for over 3 decades.
  • Developed the use of a novel treatment to reduce acute graft-versus-host disease following stem cell transplant
  • Continued innovative trials in graft-versus-host-disease prevention and treatment
  • Leaders in novel CAR-T cell treatments for blood cancers and solid tumors.
  • Evolved the treatment guidelines for patients with multiple myeloma who need a stem cell transplant, from the newly diagnosed patient to those with relapsed or refractory disease.
  • Pioneered standard of care and protocols for early use of stem cell transplants in multiple myeloma treatment, helping newly diagnosed patients achieve longer-term remissions.
  • Contributed to new guidelines for the use of salvage hematopoietic cell transplantation (HCT) in relapsed multiple myeloma.
  • Established the treatment protocol for treating metastatic testicular cancer using a regimen of high-dose chemotherapy with carboplatin and etoposide followed by a stem cell transplant using the patients’ own peripheral blood stem cells. This breakthrough treatment cures 60% of these patients.
  • Served as one of the first sites in the country to access CAR-T cell therapies to achieve long-term remission in subtypes of lymphoma and leukemia.

Why IU Health?

At IU Health Medical Center, your patients can access leading-edge cellular therapy. Our care team is shaping the future of cancer treatment with more than 30 years of clinical breakthroughs in these types of cancer. IU Health Medical Center continues to be nationally recognized by U.S. News & World Report Best Hospitals rankings, and our cancer program is rated high performing in 2025.

Our research and clinical teams in the IU Health Blood and Bone Marrow Stem Cell Transplant & Immune Cell Therapy Program have:

  • Developed the groundbreaking use of cord blood to treat cancer and immune disorders, now a reliable procedure that has been used for over 3 decades.
  • Developed the use of a novel treatment to reduce acute graft-versus-host disease following stem cell transplant
  • Continued innovative trials in graft-versus-host-disease prevention and treatment
  • Leaders in novel CAR-T cell treatments for blood cancers and solid tumors.
  • Evolved the treatment guidelines for patients with multiple myeloma who need a stem cell transplant, from the newly diagnosed patient to those with relapsed or refractory disease.
  • Pioneered standard of care and protocols for early use of stem cell transplants in multiple myeloma treatment, helping newly diagnosed patients achieve longer-term remissions.
  • Contributed to new guidelines for the use of salvage hematopoietic cell transplantation (HCT) in relapsed multiple myeloma.
  • Established the treatment protocol for treating metastatic testicular cancer using a regimen of high-dose chemotherapy with carboplatin and etoposide followed by a stem cell transplant using the patients’ own peripheral blood stem cells. This breakthrough treatment cures 60% of these patients.
  • Served as one of the first sites in the country to access CAR-T cell therapies to achieve long-term remission in subtypes of lymphoma and leukemia.

  • Access to leading-edge clinical trials

    Leading the science in immunotherapy

  • Targeted and personalized care

    Our center provides the widest variety of treatments

  • Industry leader in BMT and immunotherapy

    We’re a site of large, multi-institutional clinical trials

  • Industry leader in BMT and immunotherapy

    We’re a site of large, multi-institutional clinical trials

Watch as Dr. Nabil Adra explains how IU Health cares for your patients with testicular cancer and metastatic germ cell tumors. "Our overall goal at IU Health is to offer the best advances for patients with testicular cancer."

Featured Physicians

Dr Jennifer Schwartz Headshot

Jennifer E. Schwartz, MD

Jennifer Schwartz serves as Interim Director of Stem Cell Transplant and Cellular Therapy at IU Health. She is the Associate Dean of Continuing Education in Healthcare Professions at the IU School of Medicine. Connect with her on Doximity.

View Profile
Varun Mittal, MD headshot

Varun Mittal, MD

Varun Mittal is an Assistant Professor of Clinical Medicine and Bone Marrow Transplant specialist. Connect with Dr. Mittal on Doximity.

View Profile
Zachary Meyer MD headshot

Zachary Meyer, MD

Zachary Meyer is an Assistant Professor of Clinical Medicine and Bone Marrow Transplant specialist. Connect with Dr. Meyer on Doximity.

View Profile

Huda S. Salman, MD, PhD

Huda Salman is the Executive Director of the Brown Center for Immnotherapy as well as the Don Brown Professor of Immunotherapy at the IU School of Medicine. She serves as the program leader for Leukemia. Connect with Dr. Salman on Doximity.

View Profile

White Papers